ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2623

Disease Activity is a Novel Imaging Biomarker Associated with Knee Pain: Data from the Osteoarthritis Initiative

Jeffrey Driban1, Jonggyu Baek2, Julieann Patarini2, Emily Kirillov3, Nhung Vo3, Michael Richard3, Ming Zhang4, Matthew Harkey5, Grace Lo6, Kate Lapane2, Shao-Hsien Liu2, Charles Eaton7, James Mackay8, Joshua Harvey2 and Timothy McAlington9, 1University of Massachusetts Chan Medical School, Marlborough, NH, 2UMass Chan Medical School, Worcester, MA, 3Tufts Medical Center, Boston, MA, 4Boston University, Westford, MA, 5Michigan State University, East Lansing, MI, 6Baylor College of Medicine / MEDVAMC, Houston, TX, 7Brown University, Pawtucket, RI, 8University of Cambridge; Norwich Medical School, San Diego, CA, 9UMass Chan School of Medicine, Arlington, MA

Meeting: ACR Convergence 2025

Keywords: Biomarkers, Magnetic resonance imaging (MRI), Osteoarthritis, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Osteoarthritis – Clinical (2621–2626)

Session Type: Abstract Session

Session Time: 3:30PM-3:45PM

Background/Purpose: Barriers to developing effective osteoarthritis (OA) therapies include the lack of standardized definitions for disease progression and structural endpoints that reliably predict changes in symptoms (e.g., pain). We recently developed a “disease activity” composite metric that combines bone marrow lesion (BML) and effusion-synovitis volumes on magnetic resonance (MR) imaging into a standardized definition of disease progression related to pain. While many imaging biomarkers are associated with pain, the clinically meaningful magnitude of change in these measures remains unclear. We aimed to examine the association between 2-year changes in disease activity and 2-year changes in knee pain and quantify thresholds of clinically meaningful change for our novel disease activity composite metric.

Methods: We conducted a longitudinal nested cohort study within the Osteoarthritis Initiative, including participants with at least possible radiographic knee OA (Kellgren-Lawrence grade ≥ 1) and mild knee pain (WOMAC pain score ≥ 10/100). We measured BML and effusion-synovitis volumes on MR images (intraclass correlation coefficients > 0.95). We assessed 4 methods to calculate the disease activity metric: 1) sum of standardized volumes, 2) z-score, 3) percentile, and 4) adjusted percentile. We used established cut-points to categorize 2-year change in pain: 1) pain improvement (< - 20), 2) minimal change (-20 to 20), and 3) worsening ( > 20). We calculated the distribution of each disease activity metric across categories of changes in WOMAC knee pain. We then used multinomial logistic regression to explore the association between 2-year changes in disease activity and categories of changes in WOMAC knee pain (3-level outcome, reference = minimal change).

Results: Among 1,295 knees (641 participants), 139 knees had meaningful pain improvement (71% female, 53% obese, 81% radiographic knee OA), 75 knees had worsening (70% female, 62% obese, 79% radiographic knee OA), and 1,081 had no meaningful change (58% female, 45% obese, 79% radiographic knee OA). Changes in each disease activity metric were associated with both pain improvement (OR= 0.46 to 0.87; Table) and pain worsening (OR= 1.16 to 2.09; Table). Among knees with minimal change in pain, most knees experienced worsening disease activity scores (Table). Median disease activity changes among participants with pain improvement or worsening may serve as a threshold for defining minimally clinically important changes to effectively distinguish most knees with minimal pain changes as having minimal disease activity changes (Table, Figure).

Conclusion: All disease activity metrics were associated with knee pain, underscoring their utility in monitoring disease activity as an indicator of pain. Most knees with minimal changes in pain had subtly worsening disease activity, which reflects the natural history of OA progression. Most knees showing clinically meaningful improvement in pain experienced improved disease activity; in contrast, knees with worsening knee pain had worsening disease activity. Our composite disease activity metric shows promise as a biomarker for defining structural progression in knee OA that is clinically relevant to pain outcomes.

Supporting image 1Table. The distribution and association of 2-year changes in disease activity (DA) metrics with categories of 2-year changes in knee pain.

Supporting image 2Figure. The distribution of 2-year changes in disease activity (DA) metrics across categories of 2-year changes in WOMAC knee pain scores, with orange reflecting clinically meaningful worsening in disease activity and blue representing clinically meaningful improvement in disease activity. Note. A. Disease activity score, B. Disease activity z-score, C. Disease activity percentile, and D. Disease activity adjusted percentile.


Disclosures: J. Driban: None; J. Baek: None; J. Patarini: None; E. Kirillov: None; N. Vo: None; M. Richard: None; M. Zhang: None; M. Harkey: None; G. Lo: None; K. Lapane: None; S. Liu: None; C. Eaton: None; J. Mackay: AstraZeneca, 3, Blue Earth Diagnostics, 3; J. Harvey: None; T. McAlington: Anika, 2, Grunenthal, 2, Kiniksk, 2, Kolon TissueGene, Inc., 2, Medipost, 2, Novan, 2, Organogenesis, 2, Regeneron, 2, Remedium-Bio, 2, Samumed, 2, Sanofi, 2, Scarcell, 2, Visor, 2.

To cite this abstract in AMA style:

Driban J, Baek J, Patarini J, Kirillov E, Vo N, Richard M, Zhang M, Harkey M, Lo G, Lapane K, Liu S, Eaton C, Mackay J, Harvey J, McAlington T. Disease Activity is a Novel Imaging Biomarker Associated with Knee Pain: Data from the Osteoarthritis Initiative [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/disease-activity-is-a-novel-imaging-biomarker-associated-with-knee-pain-data-from-the-osteoarthritis-initiative/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-is-a-novel-imaging-biomarker-associated-with-knee-pain-data-from-the-osteoarthritis-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology